Skip to main content
. 2016 May 8;2016(5):CD010529. doi: 10.1002/14651858.CD010529.pub2

Martinez‐Moragon 1997.

Methods Single centre RCT of tetracycline vs bleomycin pleurodesis in MPE (Spain)
Participants Inclusion: MPE (all cell types) causing respiratory symptoms, proved by cytological examination or pleural biopsy and an expected survival of at least one month, with a KPS ≥ 50
Exclusion: prior intrapleural instillation therapy; chest radiotherapy during the preceding two weeks; previously received systemic bleomycin; trapped lung; allergy to study drugs
70 participants randomised
Interventions All participants underwent tube thoracostomy with suction drainage until < 100 ml/day output
Tetracycline group: 1.5 g in 100 ml saline intrapleurally, with 9 ml 5% lignocaine
Bleomycin group: 60 mg in 100 ml saline intrapleurally
Tube clamped for four hours after instillation, then suction drainage. Drain removed when < 100‐150 ml/day output
Outcomes Response to pleurodesis (defined as 'complete response' (CR) (no clinical or radiological recurrence of effusion), 'partial response' (PR) (small amount of fluid re‐accumulation on CXR but no symptoms), 'failure' (re‐accumulation of fluid causing symptoms or needing thoracocentesis))
Adverse effects of the procedure
Notes People with trapped lung excluded from trial entry
For this review, CRs and PRs included as pleurodesis successes
Included in network meta‐analysis for pleurodesis efficacy, fever and pain
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Low risk Computer randomisation
Allocation concealment (selection bias) Low risk Computer randomisation
Blinding of participants and personnel (performance bias) 
 All outcomes Unclear risk No mention of blinding in the paper. Agents given in the same volume but no comment on whether appearances were similar
Blinding of outcome assessment (detection bias) 
 All outcomes Unclear risk Not stated if CXR interpretation was blinded. Other symptom and side effect outcomes could be biased if participants and personnel not blind to treatment allocation, but not stated if this was the case
Incomplete outcome data (attrition bias) 
 All outcomes Low risk 8/70 (11%) excluded from analysis due to death (5) or LTFU (3)
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk No other biases identified